| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2004;77:1168-1172
© 2004 The Society of Thoracic Surgeons
a Department of Thoracic Surgery, Marseille, France
b Department of Thoracic Oncology, Marseille, France
c Department of Pathology, Université de la Méditerranée (Aix-Marseille II), Faculty of Medicine, Sainte-Marguerite Hospital, Assistance Publique, Hôpitaux de Marseille, Marseille, France
Accepted for publication September 11, 2003.
* Address reprint requests to Dr Doddoli, Sainte-Marguerite Hospital, 270 Bd de Sainte-Marguerite, Marseille Cedex 09 13274, France
e-mail: christophe.doddoli{at}mail.ap-hm.fr
BACKGROUND: Assessment of clinical and pathologic features of large cell neuroendocrine carcinoma to confirm its specificity in the setting of high grade neuroendocrine pulmonary tumors.
METHODS: From 1989 to 2001, 123 patients with a neuroendocrine carcinoma were surgically treated in a curative intent at a single institution. According to the 1999 World Health Organization classification, 20 patients were reviewed as having a large cell neuroendocrine carcinoma. Clinical data as well as detailed pathologic analysis and survival were collected.
RESULTS: There were 18 men and 2 women. The median age was 62 years. Four patients had a preoperative diagnosis of large cell neuroendocrine carcinoma. The resections consisted of 14 lobectomies and 6 pneumonectomies. There was no operative death. Complications occurred in 7 patients (35%). Four patients had a stage I of the disease, 4 had stage II, 9 had stage III, and 3 had stage IV. At follow-up (median, 46 months), 13 patients died from general recurrence and 7 patients were still alive. Median time to progression was 9 months (range, 1 to 54 months). The 5-year survival rate was 36% (median, 49 months) and it seemed to be negatively influenced by the disease stage (54% for stage I-II vs 25% for stage III-IV; p = 0.07), the presence of metastatic lymph node (45% for N0/N1 vs 17% for N2; p = 0.12), or vessel invasion (66 vs 25%; p = 0.18).
CONCLUSIONS: Large cell neuroendocrine carcinoma predominantly occurred in men. An accurate tissue diagnosis was rarely obtained preoperatively. Although overall survival after resection was substantial, large cell neuroendocrine carcinoma frequently showed pathologic features of occult metastatic disease, such as lymph node or vessel invasion, or both.
This article has been cited by other articles:
|
|
 |
|
  M. Muraoka, S. Akamine, T. Oka, T. Tagawa, A. Nakamura, T. Tsuchiya, T. Hayashi, and T. Nagayasu Sentinel node sampling limits lymphadenectomy in stage I non-small cell lung cancer Eur. J. Cardiothorac. Surg., August 1, 2007; 32(2): 356 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Rossi, A. Cavazza, A. Marchioni, L. Longo, M. Migaldi, G. Sartori, N. Bigiani, L. Schirosi, C. Casali, U. Morandi, et al. Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFR{alpha}, PDGFR{beta}, and Met in Large-Cell Neuroendocrine Carcinoma of the Lung J. Clin. Oncol., December 1, 2005; 23(34): 8774 - 8785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Battafarano, F. G. Fernandez, J. Ritter, B. F. Meyers, T. J. Guthrie, J. D. Cooper, and G. A. Patterson Large cell neuroendocrine carcinoma: An aggressive form of non-small cell lung cancer J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 166 - 172. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
